Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal composition containing angiotensin II receptor antagonist and vitamin B

A technology of B vitamins and receptor antagonists, which is applied in the field of chemical medicine composition and treatment to prevent or delay hypertension and related diseases, and can solve the problems of no recommended drugs and limited protective effect of receptor antagonists on target organs

Active Publication Date: 2006-11-29
SHENZHEN AUSA PHARM CO LTD +2
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] There are certain problems in the clinical application of AT. receptor antagonists. First of all, their antihypertensive efficacy has a certain limit. A randomized, double-blind, multi-center clinical study was conducted on 3,700 patients with mild, moderate, and severe hypertension. Sartan 50mg, the effective rate is only 41%-54%
Secondly, AT 1 The protective effect of receptor antagonists on target organs is still limited. The LIFE study (reported at the American Heart Association Symposium in November 2003) found that treatment regimens containing the angiotensin II receptor antagonist Cozaar were more effective than those containing beta-blockers. There was no significant difference in the risk of myocardial infarction and cardiovascular death between the two groups compared with the treatment regimen of atenolol
The Seventh Report of the United States Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of Hypertension (JNC 7) also did not include AT 1 Receptor antagonists are recommended drugs for high-risk diseases such as myocardial infarction and coronary heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047]Embodiment 1. preparation of pharmaceutical composition

[0048] prescription

[0049] Losartan 50.0g

[0050] Folic acid 0.2g

[0051] Starch 45.0g

[0052] Microcrystalline Cellulose 45.0g

[0053] Sodium carboxymethyl starch (CMS Na) 5.0g

[0054] 5% povidone k-30 (solvent is absolute ethanol) QS

[0055] Magnesium stearate (MS) QS

[0056] Made into 1000 pieces

[0057] Preparation Process:

[0058] (1) Take the losartan and folic acid of the prescribed amount and pass through a 100-mesh sieve and mix them uniformly by the method of equal increments for subsequent use;

[0059] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0060] (3) Mix the starch, microcrystalline cellulose, and CMS Na according to the prescription amount and then mix them evenly with the raw material medicine that has been mixed;

[0061] (4) Add appropriate amount of binder to make soft material, granula...

Embodiment 2

[0063] Embodiment 2. preparation of pharmaceutical composition

[0064] prescription:

[0065] Valsartan 80.0g

[0066] Calcium Leucovorin 5.0g

[0067] Starch 45.0g

[0068] Microcrystalline Cellulose 35.0g

[0069] Sodium carboxymethyl starch (CMS Na) 5.0g

[0070] 5% povidone k-30 (solvent is absolute ethanol) QS

[0071] Magnesium stearate (MS) QS

[0072] Made into 1000 pieces

[0073] Preparation Process:

[0074] (1) Take the valsartan and calcium leucovorin of the prescribed amount and pass through a 100-mesh sieve and mix them uniformly by the method of increasing in equal amounts for subsequent use;

[0075] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0076] (3) Mix the starch, microcrystalline cellulose, and CMS Na according to the prescription amount and then mix them evenly with the raw material medicine that has been mixed;

[0077] (4) Add appropriate amount of binder...

Embodiment 3

[0079] Embodiment 3. preparation of pharmaceutical composition

[0080] prescription:

[0081] Irbesartan 150.0g

[0082] Folic acid 0.4g

[0083] Starch 45.0g

[0084] Microcrystalline Cellulose 35.0g

[0085] Sodium carboxymethyl starch (CMS Na) 5.0g

[0086] 5% povidone k-30 (solvent is absolute ethanol) QS

[0087] Magnesium stearate (MS) QS

[0088] Made into 1000 pieces

[0089] Preparation Process:

[0090] (1) Take the irbesartan and folic acid of the prescribed amount and pass through a 100-mesh sieve and mix them uniformly by the method of increasing in equal amounts for subsequent use;

[0091] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0092] (3) Mix the starch, microcrystalline cellulose and CMS Na according to the prescription amount, and then mix with the mixed bulk drug in equal increments;

[0093] (4) Add appropriate amount of binder to make soft material, granula...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The medicine composition consists of one of AT1 receptor antagonist, its active metabolism product, ester and salt in treating effective amount of 4-800 mg, one or several kinds one B family vitamins in treating effective amount of 0.1-50 mg, and pharmaceutically acceptable carrier. The medicine composition of the present invention has the beneficial effects of raising the treating effect of blood pressure lowering AT1 receptor antagonist, strengthening the protecting effect of blood pressure lowering AT1 receptor antagonist on target organ and reducing the incidence rate of hemorrhage of the ocular fundus, angina pectoris, myocardial infarction and other complications.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist and B vitamins, especially a chemical medicine composition for treating, preventing or delaying hypertension and related diseases, belonging to the field of pharmacy. Background technique [0002] Essential hypertension is one of the most common chronic diseases and is the main cause of serious cardiovascular diseases such as myocardial infarction, stroke, and kidney disease. The prevalence rate of hypertension in my country is 27.2%, and there are more than 130 million patients at present, and the prevalence rate of hypertension is increasing rapidly (compared with the survey in 1991), and the growth rate of the prevalence rate of hypertension among people aged 35 to 44 74% for men and 62% for women (Gu Dongfeng, Jiang He, Wu Xigui, et al. Prevalence, awareness, treatment and control of hypertension in Chinese adults. Chinese Journal of Preventive Medici...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07F9/6584A61K45/06A61P9/10A61P9/12A61P13/12A61P27/02A61P3/10
Inventor 陈光亮王琳琳李莉段炎炎徐希平
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com